AstraZeneca India, 4baseCare to enhance genomic testing for cancer patients in India
The two organisations will support advanced-stage cancer patients with targeted therapy options using affordable genomic solutions
Oncology start-up 4baseCare announced a collaboration with AstraZeneca India for advancing cancer care in India. Under this collaboration, the two organisations will support advanced-stage cancer patients with targeted therapy options using affordable genomic solutions.
As a part of the collaboration, AstraZeneca and 4baseCare will work with the oncologist community to support a large number of patients by providing these services locally and also at a low cost ultimately increasing the chances of identifying optimal treatment options thereby improving clinical outcomes.
Hitesh Goswami, CEO, 4baseCare points out, “There are 15 lakh new cancer patients diagnosed every year, and more than 60 per cent have advanced-stage cancer that can benefit from targeted therapy. 4baseCare’s vision is to make comprehensive genomic profiling as affordable and accessible as doing an MRI or PET scan is expensive. This technology could be used to guide and personalise treatment for every advanced-stage cancer patient.”
Dr Anil Kukreja, Vice President – Medical Affairs and Regulatory, AstraZeneca India adds, “AstraZeneca has always been at the forefront of bringing and enhancing access to advanced technology-based solutions for medical and patient benefits. We are committed to pushing the boundaries of science and transforming the lives of patients through the right partnerships. Our current collaboration with 4baseCare is advancing this vision and is aimed at integrating the use of advanced comprehensive genomics as a part of regular clinical practice. This will take us a step closer to strengthening the oncology ecosystem in the country thereby providing potential opportunities for improving long term outcomes significantly.”
After doing massive research in collaboration with top hospitals and oncologists from India, 4baseCare recently launched another gene panel called TARGT IndieGene panel. TARGT Indiegene, is India’s largest and first population-specific tumour gene panel derived from Whole Exome and Whole Transcriptome data from over 1,500 cancer patients across 28 different cancer types.
